Resources from the same session
Is Osimertinib the best single agent if 1st line?
Presenter: Myung-Ju Ahn
Session: ESMO Colloquium supported by Eli Lilly and Company: Are single agent TKIs still Standard of Care in EGFR mutant Non-Small Cell Lung Cancer or should they be combined with other agents?
Resources:
Slides
Webcast
Should chemotherapy be combined upfront with EGFR TKI?
Presenter: Ross Soo
Session: ESMO Colloquium supported by Eli Lilly and Company: Are single agent TKIs still Standard of Care in EGFR mutant Non-Small Cell Lung Cancer or should they be combined with other agents?
Resources:
Slides
Webcast
Is a combination of anti-angiogenic with EFGR TKI a new standard
Presenter: Martin Reck
Session: ESMO Colloquium supported by Eli Lilly and Company: Are single agent TKIs still Standard of Care in EGFR mutant Non-Small Cell Lung Cancer or should they be combined with other agents?
Resources:
Slides
Webcast
Do immune check point work in EGFR TKI?
Presenter: Edward Garon
Session: ESMO Colloquium supported by Eli Lilly and Company: Are single agent TKIs still Standard of Care in EGFR mutant Non-Small Cell Lung Cancer or should they be combined with other agents?
Resources:
Slides
Webcast
In a multiline setting, what is the best sequencing?
Presenter: Enriqueta Felip
Session: ESMO Colloquium supported by Eli Lilly and Company: Are single agent TKIs still Standard of Care in EGFR mutant Non-Small Cell Lung Cancer or should they be combined with other agents?
Resources:
Slides
Webcast
Conclusions
Presenter: Myung-Ju Ahn
Session: ESMO Colloquium supported by Eli Lilly and Company: Are single agent TKIs still Standard of Care in EGFR mutant Non-Small Cell Lung Cancer or should they be combined with other agents?
Resources:
Slides
Webcast